Topic

Societal Shifts Intelligence Research

Finvaulta tracks 309 research reports on Societal Shifts Intelligence, updated through September 6, 2026. Latest: “Back-to-School Kickstart: 10 High-Level Themes; Selectively Constructive”.

Current research reflects a critical junction in societal and economic shifts, characterized by escalating geopolitical friction and a structural evolution in artificial intelligence integration. The disruption of the 'goldilocks' economic environment by Middle East conflicts and the closure of the Strait of Hormuz has pushed Brent crude above $90/bbl, creating a tangible risk of stagflation. In the technology sector, a strategic pivot is underway from mobile chips toward edge-to-cloud AI and intelligent vehicles, with investors rotating through sub-sectors toward OEMs as high-flying momentum leaders like NVDA and GOOGL begin to stall. Macroeconomic sentiment suggests a shift in central bank focus from inflation to growth in H2 2026, forcing a prioritization of real rate spreads in foreign exchange. Institutional activity is increasingly defensive, favoring Relative Value strategies and rotating capital from high-performing industrials into financials. Furthermore, the rapid growth of levered single-stock ETFs, now exceeding $60 billion in AUM, represents a significant structural development in market participation that warrants close monitoring.

Featured reports

Back-to-School Kickstart: 10 High-Level Themes; Selectively Constructive

Goldman Sachs·Sep 6, 2026

Goldman Sachs remains selectively constructive on large-cap biopharma entering fall 2026, supported by ~18% YTD outperformance, positive earnings revisions, and innovation in cancer vaccines. Key favored names into year-end include JNJ, LLY, AMGN, RPRX, MRK, TEVA, VRTX, AZN, and Bayer, while Novartis, BMY, and PFE face higher-risk catalyst paths.

Longevity Weekly Pulse #70: GLP-1 Prescription Volumes Gain Momentum

UBS·Aug 26, 2026

The launch of the Medicare Bridge program on 1 July has accelerated anti-obesity GLP-1 prescription growth, with starter doses for Zepbound and Wegovy surging over 20% MoM in July. UBS remains constructive on the obesity drug market, which is tracking at an annualized USD 95bn run-rate with significant long-term growth potential.

How Can I Invest In Transformational Innovation

UBS·Aug 10, 2026

UBS highlights structural investment opportunities in AI, power, and longevity, advocating for a diversified approach to capture long-term growth while managing heightened volatility. They note strong capex trends for AI and robust demand in the energy transition and health care sectors.

Equity Thematic Strategy

J.P. Morgan·Jul 28, 2026

Healthcare offers a rare combination of durable growth, attractive relative valuation, and accelerating earnings potential for 2027. It remains under-owned and is positioned to benefit as investors seek to diversify away from crowded AI themes.

Longevity Weekly Pulse

UBS·Jul 8, 2026

This report provides a preview of 2Q26 health care earnings, highlighting the market focus on GLP-1 drug performance, medical device sector trends, and pivotal pharmaceutical pipeline catalysts.

Signal Over Noise: Playing Offense And Defense Through Health Care

UBS·Jun 8, 2026

This report highlights the health care sector as a strategic asset for both defense and growth, driven by the emergence of GLP-1 drugs and AI-enhanced drug discovery. UBS emphasizes that these factors create a compelling long-term opportunity despite the sector's previous underperformance compared to other growth themes.

Global Healthcare: The Obesity Evolution

Goldman Sachs·Jun 5, 2026

This report examines the global production capacity for Anti-Obesity Medication (AOM) peptides, specifically comparing Novo Nordisk's proprietary fermentation processes with synthetic (SPPS) manufacturing used by global CDMOs. It projects significant market growth for peptide API demand, largely driven by the adoption of oral GLP-1 therapies.

Longevity Offers Long Term Growth Potential

UBS·May 14, 2026

UBS highlights Longevity as a multi-trillion dollar secular growth theme that offers diversification against AI-heavy portfolios. Despite recent US inflation spikes, the Fed is expected to cut rates starting in late 2026.

AstraZeneca: Etcamah (Camizestrant) FDA Approval in 1L Breast Cancer Switch Setting a Positive Surprise

Goldman Sachs·Sep 7, 2026

Longevity Weekly Pulse: Strong 1H26 Results from WuXi Biologics and Innovent

UBS·Sep 2, 2026

International Market Intelligence: Morning Briefing

J.P. Morgan·Aug 28, 2026

All reports

Page 1 of 13

Use in AI assistants

Search this research archive inside ChatGPT, Claude, or Perplexity.

ChatGPT Claude Perplexity

LLY Health Care Equities UBS NVO Information Technology

Get full access

Create an account to follow this research